Bacopa monnieri 用于 记忆力减退
A 证据 多项大型临床试验一致显示出显著的益处。Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dbacopa\u002Dmonnieri\u0026condition\u003Dmemory\u002Dloss';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
结论
Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
Key Study Findings
Systematic Review
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.
Dose: None
vs: None
Outcome: Cholinesterase inhibition and cognitive improvement
效果: None
None
研究人群: In vivo animal models of AD
Other
Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus …
Dose: 200 mg/kg body weight
vs: Rotenone-PD mice without BME
Outcome: Recognition memory and AMPA receptor expression
效果: None
None
研究人群: Rotenone-induced Parkinson's disease mouse model
Review
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.
Dose: None
vs: None
Outcome: Cognitive decline
效果: None
None
研究人群: Alzheimer's disease patients
Other
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma.
Dose: Bacopa monnieri (Brahmi)
vs: None
Outcome: Immunomodulatory effects in breast cancer
效果: None
None
研究人群: Retracted publication - invasive ductal carcinoma
In Vitro
Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and …
Dose: Bacopa monnieri phytocompounds
vs: Standard AChE inhibitors
Outcome: AChE inhibition and neuroprotection
效果: None
None
研究人群: In silico/in vitro NDD study
In Vitro
Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells.
Dose: None
vs: None
Outcome: oxidative stress markers
效果: None
None
研究人群: None
Key Statistics
22
研究数量
1800
受试者
↑
Positive
A
等级
Referenced Papers
Brain sciences
2025
14 次引用
Molecular neurobiology
2025
3 次引用
Current Alzheimer research
2024
10 次引用
Medical oncology (Northwood, …
2024
2 次引用
Heliyon
2023
20 次引用
International journal of …
2023
13 次引用
The Senior care …
2021
2 次引用
Scientific reports
2021
1 次引用
Brain sciences
2020
72 次引用
Annals of Indian …
2020
17 次引用
Drug target insights
2019
103 次引用
Current neuropharmacology
2019
53 次引用
Epilepsy & behavior …
2018
28 次引用
Journal of ethnopharmacology
2017
98 次引用
PloS one
2015
51 次引用
Evidence-based complementary and …
2015
14 次引用
Neurochemical research
2012
85 次引用
Recent patents on …
2011
132 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
上限： Not established; well-tolerated up to 600 mg/day in trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| 200 mg/kg body weight | -- | Positive | -- |
| None | -- | Mixed | -- |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| Bacopa monnieri phytocompounds | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
最佳服用时间： With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
已报告的副作用
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
已知相互作用
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
可耐受最高摄入量： Not established; well-tolerated up to 600 mg/day in trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Bacopa monnieri help with 记忆力减退?
Based on 22 studies with 1,800 participants, there is strong evidence from multiple clinical trials that Bacopa monnieri may support 记忆力减退 management. Our evidence grade is A (Strong Evidence).
How much Bacopa monnieri should I take for 记忆力减退?
Studies have used various dosages. A commonly studied range is 300-600 mg/day standardized to 50% bacosides. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacopa monnieri?
Reported side effects may include Gastrointestinal discomfort (nausea, cramping, diarrhea), Dry mouth, Fatigue in some individuals, Mild sedation at higher doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacopa monnieri and 记忆力减退?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 22 peer-reviewed studies with 1,800 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 记忆力减退
Bacopa monnieri 用于其他健康状况
References
- [1] Maryam N ALNasser et al.. Brain Sci. 2025. Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review. doi:10.3390/brainsci15020215 PubMed
- [2] Vartika Gupta et al.. Mol Neurobiol. 2025. Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus Are Associated with Recognition Memory … doi:10.1007/s12035-024-04392-1 PubMed
- [3] Debasis Sen et al.. Curr Alzheimer Res. 2024. Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration. doi:10.2174/0115672050309057240404075003 PubMed
- [4] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [5] Shehla Shoukat et al.. Heliyon. 2023. Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research. doi:10.1016/j.heliyon.2023.e21161 PubMed
- [6] Tushar Dubey et al.. Int J Biol Macromol. 2023. Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells. doi:10.1016/j.ijbiomac.2023.123171 PubMed
- [7] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [8] James M Brimson et al.. Sci Rep. 2021. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. doi:10.1038/s41598-020-80045-2 PubMed
- [9] Jogender Mehla et al.. Brain Sci. 2020. Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. doi:10.3390/brainsci10120964 PubMed
- [10] Sudesh Prabhakar et al.. Ann Indian Acad Neurol. 2020. Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b … doi:10.4103/aian.AIAN_610_19 PubMed
- [11] Aimi Syamima Abdul Manap et al.. Drug Target Insights. 2019. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical … doi:10.1177/1177392819866412 PubMed
- [12] Vini C Sekhar et al.. Curr Neuropharmacol. 2019. Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. doi:10.2174/1570159X16666180419123022 PubMed
- [13] Amrita Mishra et al.. Epilepsy Behav. 2018. Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of … doi:10.1016/j.yebeh.2017.12.040 PubMed
- [14] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [15] Surya P Pandey et al.. PLoS One. 2015. Alterations in Hippocampal Oxidative Stress, Expression of AMPA Receptor GluR2 Subunit and Associated Spatial Memory Loss by Bacopa monnieri Extract … doi:10.1371/journal.pone.0131862 PubMed
- [16] Anupama Rani et al.. Evid Based Complement Alternat Med. 2015. A Special Extract of Bacopa monnieri (CDRI-08)-Restored Memory in CoCl2-Hypoxia Mimetic Mice Is Associated with Upregulation of Fmr-1 Gene Expression … doi:10.1155/2015/347978 PubMed
- [17] Neetu Saini et al.. Neurochem Res. 2012. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. doi:10.1007/s11064-012-0811-4 PubMed
- [18] G K Shinomol et al.. Recent Pat Endocr Metab Immune Drug Discov. 2011. Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy. doi:10.2174/187221411794351833 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。